ArticleBiosensors2022
Label-Free LSPR-Vertical Microcavity Biosensor for On-Site SARS-CoV-2 Detection.
Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Optical biosensing of monkeypox virus using novel recombinant silica-binding proteins for site-directed antibody immobilization.Journal of pharmaceutical analysis · 2024Article
- Optical biosensors for diagnosis of COVID-19: nanomaterial-enabled particle strategies for post pandemic era.Mikrochimica acta · 2024Review
- Rapid assays of SARS-CoV-2 virus and noble biosensors by nanomaterials.Nano convergence · 2024Review
- Impact of nanotechnology on conventional and artificial intelligence-based biosensing strategies for the detection of viruses.Discover nano · 2023Review
- Biosensors for waterborne virus detection: Challenges and strategies.Journal of pharmaceutical analysis · 2023Review
- Simultaneous Detection of SARS-CoV-2 Nucleoprotein and Receptor Binding Domain by a Multi-Area Reflectance Spectroscopy Sensor.Biosensors · 2023Article
- Machine Learning Techniques for Effective Pathogen Detection Based on Resonant Biosensors.Biosensors · 2023Article
- Heterogeneous-Nucleation Biosensor for Long-Term Collection and Mask-Based Self-Detection of SARS-CoV-2.Biosensors · 2023Article
- Challenges and perspectives of multi-virus biosensing techniques: A review.Analytica chimica acta · 2023Review
- Progress in Biosensors for the Point-of-Care Diagnosis of COVID-19.Sensors (Basel, Switzerland) · 2022Review
- Label-free optical biosensors in the pandemic era.Nanophotonics (Berlin, Germany) · 2022Review
- Review
- A loop-mediated isothermal amplification-enabled analytical assay for the detection of SARS-CoV-2: A review.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cost-effective, rapid, and sensitive detection of SARS-CoV-2, in high-throughput, is crucial in controlling the COVID-19 epidemic. In this study, we proposed a vertical microcavity and localized surface plasmon resonance hybrid biosensor for SARS-CoV-2 detection in artificial saliva and assessed its efficacy. The proposed biosensor monitors the valley shifts in the reflectance spectrum, as induced by changes in the refractive index within the proximity of the sensor surface. A low-cost and fast method was developed to form nanoporous gold (NPG) with different surface morphologies on the vertical microcavity wafer, followed by immobilization with the SARS-CoV-2 antibody for capturing the virus. Modeling and simulation were conducted to optimize the microcavity structure and the NPG parameters. Simulation results revealed that NPG-deposited sensors performed better in resonance quality and in sensitivity compared to gold-deposited and pure microcavity sensors. The experiment confirmed the effect of NPG surface morphology on the biosensor sensitivity as demonstrated by simulation. Pre-clinical validation revealed that 40% porosity led to the highest sensitivity for SARS-CoV-2 pseudovirus at 319 copies/mL in artificial saliva. The proposed automatic biosensing system delivered the results of 100 samples within 30 min, demonstrating its potential for on-site coronavirus detection with sufficient sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.